A Gene Therapy's Cancer Signal, Plus Claude Fable 5.2's Price Cut | Tech Arcade Podcast

Nov 10, 2026 · News · Startups & funding

The F.D.A. has confirmed that the delivery virus in Novartis' two million dollar gene therapy Zolgensma inserted itself next to a cancer gene in two children, among nine tumour reports. Then Anthropic's Claude Fable 5.2 and Mythos 5.2: a 20% price cut, faster outputs, and what the system card says about models that suspect they are being tested.

Full story: https://www.techarcade.io/nine-tumors-one-cancer-gene-the-fda-is-investigating-a-2-1-million-gene-therapy/

Full story: https://www.techarcade.io/anthropic-just-launched-claude-fable-5-2-20-cheaper-and-up-to-30-faster-weeks-before-its-i/

Sources

https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-malignancy-linked-zolgensma-gene-therapy

https://www.rttnews.com/3711442/fda-investigates-cancer-risk-associated-with-novartis-zolgensma-gene-therapy.aspx

https://www.techtimes.com/articles/330219/20261107/fda-confirms-gene-therapy-zolgensma-activated-cancer-gene-children-extends-investigation-itvisma.htm

https://www.anthropic.com/claude-fable-and-mythos-5-2

https://techcrunch.com/2026/11/09/anthropic-releases-new-mythos-and-fable-models-amid-rsi-concerns/

https://finance.yahoo.com/technology/article/anthropic-debuts-claude-fable-52-and-mythos-52-models-as-ipo-nears-190405087.html

Where sources differ: the nine-report count comes from Novartis' disclosure as reported by RTTNews and TechTimes; the FDA notice itself gives no total.

More at https://www.techarcade.io

#techarcade #genetherapy #anthropic #ai #technews

Watch on YouTube ↗Subscribe

▶ More videos

Video library →